Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

Three cycles of neoadjuvant nivolumab plus chemotherapy significantly improved overall survival among patients with resectable NSCLC as compared with chemotherapy alone. (Funded by Bristol Myers Squibb; CheckMate 816 ClinicalTrials.gov number, NCT02998528.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-06-02
DOI
https://doi.org/10.1056/nejmoa2502931
Citations
94
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
98.27

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

S. Meadows–Shropshire, Tudor–Eliade Ciuleanu, Steven Swanson, Simi Bhatia et al.
94 citations
New England Journal of Medicine
Cancer Immunotherapy and Biomarkers
98.27
article

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

S. Meadows–Shropshire, Tudor–Eliade Ciuleanu, Steven Swanson, Simi Bhatia, Gene B. Saylors, Moïshe Liberman, Julie R. Brahmer, Joseph Fiore, Stephen Broderick, Fumihiro Tanaka, Janis M. Taube, Quyen Duong, Hiroyuki Ito, Lily Wang, Claudio Martín, Jonathan Spicer, Patrick M. Forde, Tetsuya Mitsudomi, Mariano Provencio, Mark M. Awad, Enriqueta Felip, Nicolas M Girard, Changli Wang, Junliang Cai, Ke-Neng Chen, Keith M. Kerr, Shun Lu
article en
94 citations

Abstract

Three cycles of neoadjuvant nivolumab plus chemotherapy significantly improved overall survival among patients with resectable NSCLC as compared with chemotherapy alone. (Funded by Bristol Myers Squibb; CheckMate 816 ClinicalTrials.gov number, NCT02998528.).

New England Journal of MedicineVol. 393(8)
Hebron University (PS), Brigham and Women's Hospital (US), Bloomberg (United States) (US), Memorial Sloan Kettering Cancer Center (US), Johns Hopkins University (US), Shanghai Jiao Tong University (CN), University of Occupational and Environmental Health Japan (JP), Peking University (CN), Trinity College Dublin (IE), Johns Hopkins Medicine (US), Aberdeen Royal Infirmary (GB), Cancer Institute (WIA) (IN), McGill University Health Centre (CA), Tianjin Medical University Cancer Institute and Hospital (CN), Shanghai Chest Hospital (CN), Kanagawa Prefectural Hospital Organization (JP), Bristol-Myers Squibb (United States) (US), Peking University Cancer Hospital (CN), Institute of Oncology Prof. Dr. Ion Chiricuta (RO), Hospital Universitario Puerta de Hierro Majadahonda (ES), Instituto Alexander Fleming (AR), Centre Hospitalier de l’Université de Montréal (CA), Institut du Thorax (FR), Molecular Oncology (United States) (US), Sidney Kimmel Comprehensive Cancer Center (US), Kanagawa Cancer Center, Vall d'Hebron Institute of Oncology (ES), Institut Curie (FR), Kindai University (JP)
Bristol-Myers Squibb
Openalex Percentile: Top 0%
Cancer Immunotherapy and Biomarkers
98.27
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.